ANALISIS EFEKTIVITAS BIAYA ANTIBIOTIK SEFOTAXIME DAN GENTAMISIN PENDERITA PNEUMONIA PADA BALITA DI RSUD KABUPATEN BOMBANA PROVINSI SULAWESI TENGGARA
Pneumonia is a disease that is problem in many developing countries including Indonesia. Antibiotics is a major therapy in the treatment of pneumonia. Pneumonia in infants requires appropriate antibiotic therapy and is in accordance with the minimal risk of the side effects and the cost of affordabl...
Saved in:
Published in | JIIS (Jurnal Ilmiah Ibnu Sina) (Banjarmasin) Vol. 3; no. 1; pp. 1 - 11 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Sekolah Tinggi Ilmu Kesehatan ISFI Banjarmasin
01.03.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Pneumonia is a disease that is problem in many developing countries including Indonesia. Antibiotics is a major therapy in the treatment of pneumonia. Pneumonia in infants requires appropriate antibiotic therapy and is in accordance with the minimal risk of the side effects and the cost of affordable health services. This study aims to analyze the effectiveness of antibiotic costs of patients with pneumonia in infants at RSUD Bombana city in 2016. The research method is descriptive with cross sectional study design. Data were retrospectively in both the exclusion and inclusion criteria. Total costs are antibiotic costs, hospitalization costs, laboratory costs and other drug costs. The effectiveness of therapy basede the length of patients treated and declared cured. The effectiveness of treatment analyzed using ACER (Average Cost Effectiveness Ratio) was calculated based on the cost ratio and (percent)% of clinical outcome in the cefotaxime and gentamicin groups. The results showed that from 30 patients in the inclusion criteria, the total cost of cefotaxime antibiotics was Rp.3,000,000 and gentamicin was Rp.3,264,000. The effectiveness of cefotaxime antibiotic use was 81.25% while gentamicin was 85.71%. ACER cefotaxime value of 36.923 and gentamicin amounted to 38.081. Based on the value of ACER, the cost-effective treatment cost is cefotaxime. |
---|---|
ISSN: | 2502-647X 2503-1902 |